Research programme: microRNA therapeutics - GlaxoSmithKline/Regulus Therapeutics

Drug Profile

Research programme: microRNA therapeutics - GlaxoSmithKline/Regulus Therapeutics

Alternative Names: miR-122 inhibitors - GlaxoSmithKline/Regulus; miR-146 inhibitors - GlaxoSmithKline/Regulus; miR-155 inhibitors - GlaxoSmithKline/Regulus; miR-181a inhibitors - GlaxoSmithKline/Regulus

Latest Information Update: 11 Jul 2014

Price : $50

At a glance

  • Originator Regulus Therapeutics LLC
  • Developer GlaxoSmithKline; Regulus Therapeutics
  • Class MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; MIRN122 microRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis C; Inflammation

Most Recent Events

  • 09 May 2014 Preclinical development is ongoing for Inflammation in USA (Regulus 10-Q)
  • 14 May 2013 Preclinical development is ongoing for Hepatitis C
  • 11 Feb 2011 Preclinical pharmacodynamics data released by Regulus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top